Advanced Catheter Therapies, Inc.

Advanced Catheter Therapies, Inc. focuses on developing innovative medical devices to improve treatment methods for peripheral arterial disease, ensuring targeted delivery of therapeutic agents during vascular procedures. Founded in 2008 in Chattanooga, US, Advanced Catheter Therapies, Inc. is dedicated to advancing treatment options for peripheral arterial disease.

The company has pursued a Series B funding round, raising USD 0. 4 mn from TAM Ventures in March 2015. The firm has completed a total of 5 deals since its inception, solidifying its position in the medical device market under the leadership of CEO Paul Fitzpatrick, with founders Dirk Hoyns and Don White contributing to its establishment. Advanced Catheter Therapies (ACT) specializes in the development of the Pressana Occlusion Perfusion Catheter (OPC), a patented medical device designed for targeted delivery of therapeutic agents to treat peripheral arterial disease (PAD).

This device creates a localized treatment chamber for controlled delivery and evacuation of agents like anticoagulants, significantly addressing the need in vascular procedures and reducing lower limb amputation rates. Advanced Catheter Therapies has generated USD 7. 8 mn in sales from the Pressana OPC, which includes licensing fees. Their business model is based on B2B sales through partnerships with healthcare facilities and distributors, enhancing product reach and market penetration, facilitated by multiple FDA clearances that support their market presence.

Advanced Catheter Therapies aims to utilize the recent USD 0. 4 mn raised in Series B funding to enhance product development and market strategies. They are focusing on expanding their offerings with new products and targeting broader geographic regions for distribution, specifically aiming to enter additional markets within the US healthcare sector by 2025. The funds from the latest financing round will support these initiatives, allowing for increased research and development activities.